Real-world evidence of long-term durability and efficacy of faricimab as an advanced treatment line for NVAMD and DME

Purpose: To evaluate the efficacy and durability of intravitreal Faricimab (Vabysmo) in patients with neovascular age-related macular degeneration (NVAMD) and diabetic macular edema (DME). Methods: A retrospective study was conducted at a tertiary ophthalmology center. Eyes with NVAMD or DME which had received previous Anti-vascular endothelial growth factor (A-VEGF) treatment before switching to Faricimab were included. Best-corrected visual acuity (BCVA), central subfield thickness (CST), and injection intervals were recorded at baseline and follow-up visits of up to 2.5 years. Results: A total of 192 eyes (160 with NVAMD and 32 with DME) from 155 patients were included. The mean patient age was 79.5 ± 9.6 years, with an average follow-up duration of 468.1 ± 120.4 days from baseline. In the NVAMD cohort, BCVA improved from 0.43 ± 0.33 logMAR at baseline to 0.34 ± 0.30 at 1.5 years (p < 0.05). CST decreased significantly from a mean of 308.3 ± 65.3 Micrometers to 242.4 ± 44.8 Micrometers at two years (p < 0.001). The mean interval between injections increased from a mean of 33.9 ± 9.6 days at baseline to 77.6 ± 42.6 days at two years, reflecting a significant extension throughout the observation period (p < 0.001). In eyes with DME, CST declined from 403.6 ± 121.9 Micrometers at baseline to 303.2 ± 105.2 Micrometers at one year (p < 0.001), while BCVA remained stable. Injection intervals extended from 34.4 ± 10.3 to 60.9 ± 20.5 days at one year (p < 0.001). Conclusion: In this study of previously treated eyes with NVAMD and DME, Faricimab demonstrated sustained anatomical and functional benefits alongside meaningful injection interval extension.